Cost of carcinoid syndrome (CS) In France: Analysis of the national health insurance database

#3182

Introduction: CS develops in approximately 20% of patients with neuroendocrine tumors (NET). The cost of its management has never been studied in France.

Aim(s): To describe the cost of care in patients with NET and CS using the French national health insurance database.

Materials and methods: Patients were included in the analysis if they had a hospital stay associated with the code E34.0 "CS" and at least one delivery of a somatostatin analogue (SSA) between 01/01/2012 and 31/12/2016. The end of the analysis was either 31/12/2017 or the date of death, whichever came first. Here, we describe mean overall costs, by item of expenditure, and by periods: 1st year in incident CS diagnosis (incident was defined as a patient naïve to SSA or hospitalization with the code E34.0 before 01/01/2013) and last year in deceased patients.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Walter T

Authors: Perrier M, Mouawad C, Gueguen D, Bouille C, Laborey M,

Keywords: carcinoid syndrome, resources, healthcare expenditure,